SANGSTAT MEDICAL CORP SANG Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$4.59 up $0.12, 2.68% at close Nov 6
Last close · Previous close $4.47
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.72Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$4.59down $0.26, 5.36%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$4.47Nov 5
- Volume89.07KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume66.76KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.40 to $5.42; now $4.59
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SANG beat the S&P 500 in 2 of 5 periods.
| Period | SANG and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SANG: down 5.4% S&P 500: down 5.6% | SANG beat the S&P 500 by 0.2 percentage points Beat |
| 3M | SANG: up 14.5% S&P 500: down 4.1% | SANG beat the S&P 500 by 18.6 percentage points Beat |
| YTD | SANG: down 9.4% S&P 500: up 8.7% | SANG trailed the S&P 500 by 18.1 percentage points Trailed |
| 1Y | SANG: down 5.4% S&P 500: up 10.9% | SANG trailed the S&P 500 by 16.3 percentage points Trailed |
| Long term | ||
| 3Y | SANG: up 49.0% S&P 500: up 75.0% +14.2% vs +20.5% a year | SANG trailed the S&P 500 by 26.0 percentage points Trailed |
$10,000 invested in SANG a year ago (Nov 6, 2025) would be worth about $9,464 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
SANG beat the S&P 500 in 2 of 5 periods.
| Period | SANG and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SANG: down 5.4% S&P 500: down 5.6% | SANG beat the S&P 500 by 0.2 percentage points Beat |
| 3M | SANG: up 14.5% S&P 500: down 4.3% | SANG beat the S&P 500 by 18.8 percentage points Beat |
| YTD | SANG: down 9.4% S&P 500: up 7.8% | SANG trailed the S&P 500 by 17.2 percentage points Trailed |
| 1Y | SANG: down 5.4% S&P 500: up 9.7% | SANG trailed the S&P 500 by 15.1 percentage points Trailed |
| Long term | ||
| 3Y | SANG: up 49.0% S&P 500: up 68.8% +14.2% vs +19.1% a year | SANG trailed the S&P 500 by 19.8 percentage points Trailed |
$10,000 invested in SANG a year ago (Nov 6, 2025) would be worth about $9,464 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$18.80
Closing high on . Now 75.6% below that record.
Split-adjusted daily closes since Nov 8, 2021.
Stock splits
1
1-for-7 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $143.68Mdown 15.3%
- Net income
- −$57.19M
- Diluted EPS
- −$1.72
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY25 (Sep 30, 2024) | $44.46M | −$1.41M | −$0.04 |
| Q2 FY25 (Dec 31, 2024) | $41.19M | −$1.31M | −$0.04 |
| Q3 FY25 (Mar 31, 2025) | $40.35M | −$992.36K | −$0.03 |
| Q4 FY25 (Jun 30, 2025) | $43.62M | $153.56K | $0.01 |
| Q1 FY26 (Sep 30, 2025) | $36.51M | −$1.68M | −$0.05 |
| Q2 FY26 (Dec 31, 2025) | $37.55M | −$1.46M | −$0.04 |
| Q3 FY26 (Mar 31, 2026) | $36.69M | −$1.68M | −$0.05 |
| Q4 FY26 (Jun 30, 2026) | $32.94M | −$52.38M | −$1.58 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $174.32M | −$86.08M | −$2.74 |
| FY23 (Jun 30, 2023) | $190.59M | −$21.91M | −$0.66 |
| FY24 (Jun 30, 2024) | $180.90M | −$6.33M | −$0.19 |
| FY25 (Jun 30, 2025) | $173.91M | −$3.68M | −$0.11 |
| FY26 (Jun 30, 2026) | $140.79M | −$57.07M | −$1.72 |
Margins
- Gross 70.4%
- Operating −41.5%
- Net −39.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $11.34MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$17.11MLast 12 months
- Capital spending$5.77MLast 12 months
- 7.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $643.44KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $7.39MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$24.05MAs of Jun 30, 2026
- Net debt$16.67MAs of Jun 30, 2026
- 0.78As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.20As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −34.4%Last 12 months
Over the last 12 months, SANGSTAT MEDICAL lost money: its net loss was 34.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −26.2%Last 12 months
Over the last 12 months, SANGSTAT MEDICAL’s net loss was 26.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About SANGSTAT MEDICAL CORP
DELISTED - SANGSTAT MEDICAL CORP
- Sector
- Technology
- Industry
- Software - Infrastructure
- Headquarters
- Ontario, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SANG news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SANG stock FAQ
What is SANG stock’s price today?
SANGSTAT MEDICAL (SANG) traded at $4.59 at the close on , up $0.12 (2.68%) from the previous close of $4.47. Over the past 52 weeks it has traded between $3.40 and $5.42.
What is SANG’s P/E ratio?
SANG’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.72).
How much revenue does SANGSTAT MEDICAL make?
SANGSTAT MEDICAL reported $143.7 million of revenue over the four quarters to , down 15.3% from the twelve months before. In its latest quarter (Q4 FY26, ended ) revenue was $32.9 million, down 24.5% from a year earlier.
Is SANGSTAT MEDICAL profitable?
Not over the four quarters to . SANGSTAT MEDICAL reported a net loss of $57.2 million across those four quarters on $143.7 million of revenue.
What are SANG’s earnings per share?
SANG’s diluted earnings per share were −$1.72 over the four quarters to , compared with −$0.11 in the twelve months before. The latest quarter (Q4 FY26) brought −$1.58 per share, against $0.01 a year earlier (how EPS works).
Does SANG pay a dividend?
SANGSTAT MEDICAL hasn’t paid a dividend in the last twelve months.
What is SANG’s 52-week high and low?
Over the past 52 weeks SANG has traded as low as $3.40 and as high as $5.42. At $4.59 at the close on , it is 15.2% below that high and 35.0% above the low.
What is SANG’s all-time high?
SANG’s highest closing price was $18.80 on , adjusted for stock splits. At $4.59 at the close on , it is 75.6% below that record.
Has SANG stock ever split?
Yes, once: 1-for-7 on .
How has SANG stock performed?
Including dividends and measured to the close on , SANG has returned −9.4% so far this year and −5.4% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is SANGSTAT MEDICAL in?
SANGSTAT MEDICAL is in the Technology sector and the Software - Infrastructure industry, and is headquartered in Ontario, Canada.
What exchange does SANG trade on?
SANGSTAT MEDICAL trades on the Nasdaq under the ticker symbol SANG. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.